DOI QR코드

DOI QR Code

Suggestion of A Practical Simple Calculation Method for Safe Transportation Time after Radioactive Iodine Treatment in Patients with Thyroid Cancer

갑상선암 환자에서 방사성옥소치료 후 안전하게 이동할 수 있는 시간을 계산하기 위한 실용적인 간편계산법 제안

  • Received : 2015.02.10
  • Accepted : 2015.06.11
  • Published : 2015.06.30

Abstract

When a patient with thyroid cancer is released from isolation after I-131 treatment and return to home using a vehicle, travel time should be controlled to reduce the amount of radiation to accompanying person. As the calculation of appropriate travel time is difficult, there is no patient-specific guideline until now. If we assume that there is no excretion and no physical decay during the relatively short travel time, calculation become quite simple; total radiation dose = dose rate ${\times}$ travel time. Results of this simple calculation and conventional calculation were compared using datum from 120 patients. Travel time calculated by simple method was 56% of conventional method in 0.3 m, 91% in 0.5 m and 96% in 1 m. Simple method was safe. It can be applied easily and also can be applied to the patients with hyperthyroidism treated by I-131.

Keywords

I-131;radiation safety;thyroid cancer;treatment

References

  1. Marcus Middendorp, MD, and Frank Grunwald, MD. Update on Recent Developments in the Therapy of Differentiated Thyroid Cancer. Semin Nucl Med 40:145-152, 2010. DOI: http://dx.doi.org/10.1053/j.semnuclmed.2009.10.006 https://doi.org/10.1053/j.semnuclmed.2009.10.006
  2. Hee Jeong Park, Geum-Cheol Jeong, Seong Young Kwon, Jung-Joon Min, Hee-Seoung Bom, Ki Seong Park, Sang-Geon Cho, Sae-Ryung Kang, Jahae Kim, Ho-Chun Song, Ari Chong, Su Woong Yoo. Stimulated Serum Thyrogolbulin Level at the Time of First Dose of Radioactive Iodine Therapy is the Most Predictive Factor for Therapeutic Failure in Patients with Papillary Thyroid Carcinoma. Nucl Med Mol Imaging 48:255-261, 2014. DOI: http://dx.doi.org/10.1007/s13139-014-0282-4 https://doi.org/10.1007/s13139-014-0282-4
  3. Release of Patients after Therapy with Unsealed Radionuclides. ICRP Publication 94. Ann. ICRP 34(2). 2004.
  4. Leonard R, Coover, Edward B. Silberstein, Phyllis J. Kuhn, and Mark W. Graves. Therapeutic $^{131}I$ in Outpatients: A Simplified Method Conforming to the Code of Federal Regulations, Title 10, Part 35.75. J Nucl Med 41:1868-1875, 2000.
  5. Sungmin Kang, MD, Byung Il Kim, MD, In-Ju Kim, MD, Hee-Seung Bom, MD, Ga Hee Lee MD, Jaetae Lee, MD, Woong Youn Chung, MD, and Jae Hoon Chung, MD. Radiation Safety in the Treatment of Patients with Thyroid Disease by $^{131}I$. J Korean Thyroid Assoc 5:6-20, 2012. DOI: http://dx.doi.org/10.11106/jkta.2012.5.1.6 https://doi.org/10.11106/jkta.2012.5.1.6
  6. Jai Hyuen Lee, Seok Gun Park. Estimation of the Release Time from Isolation for Patients with Differentiated Thyroid Cancer Treated with High-dose I-131. Nuc Med Mol Imaging 44:241-245, 2010. DOI: http://dx.doi.org/10.11106/jkta.2012.5.1.6 https://doi.org/10.1007/s13139-010-0041-0
  7. Cheryl M, Culver and Howard J. Dworkin. Radiation Safety Considerations for Post-Iodine-131 Thyroid Cancer Therapy. J Nucl Med 33:1402-1405, 1992.
  8. Hee-Myung Park, MD., Jung Woong Jang, NMT., Hee Chul Yang, NMT., and Young Gook Kim, NMT. Outpatient Radioablation Therapy for Thyroid Cancer Patients with Minimal Radiation Exposure to the Family Members. Nucl Med Mol Imaging 41: 218-225, 2007.
  9. Sally F. Barrington, Michaell J. O'Doherty, Andrew G. Kettlee, William H. Thomson, Peter J. Mountford, David N. Burrell, Robert J. Farrell, Stanley Bachelor, Paul Seed, L. keith Harding. Radiation Exposure of the Families of Outpatients Treated with Radioiodine (iodine-131) for Hyperthyroidism. Eur J Nucl Med 26:686-692, 1999. https://doi.org/10.1007/s002590050438
  10. Siegel JA, Marcus CS, Stabin MG. Licensee Over-relaiance on Conservatisms in NRC Guidance Regarding the Release of Patients Treated with I-131. Health Phys 93:667-677, 2007. DOI: http://dx.doi.org/10.1097/01.HP.0000270300.34270.44 https://doi.org/10.1097/01.HP.0000270300.34270.44
  11. James C. Sisson, John Freitas, Ian Ross McDougall, Lawrence T. Dauer, James R. Hurley, James D. Brierley, Charlotte H. Edinboro, David Rosenthal, Michael J. Thomas, Mira A. Wexler, Ernest Asamoah, Anca M. Avram, Mira Milas, and Carol Greenlee. Radiation Safety in the Treatment of Patients with Thyroid Diseases by Radioiodine $^{131}I$: Practice Recommendations of the American Thyroid Association. The Americal Thyroid Association Taskforce on Radiation Safety. Thyroid 21:355-346, 2011. https://doi.org/10.1089/thy.2010.0315
  12. Coover LR, Silberstein EB, Kuhn PJ, Graves MW. Therapeutic $^{131}I$ in outpatients: A Simplified Method Conforming to the Code of Fedreral Regulations, Title 10, Part 35.75. J Nucl Med 41:1868-75, 2000.
  13. David L. North, Douglas R. Shearer, James V. Hennessy, and Glenn L. Donovan. Effective Half-life of $^{131}I$ in Thyroid Cancer Patients. Health Phys 81:325-329, 2001. DOI: http://dx.doi.org/10.1097/00004032-200109000-00013 https://doi.org/10.1097/00004032-200109000-00013
  14. Markus Luster, Steven I. Sherman, Monica C. Skarulis, James R. Reynolds, Michael Lassmann, Heribert Hanscheid, Christoph Reiners. Comparison of Radioiodine Biokinetcs following the Administration of Recombinant Human Thyroid Stimulating Hormone and after Thyroid Hormone withdrawal in Thyroid Carcinoma. Eur J Nucl Med Mol Imaging 30:1371-1377, 2003. DOI: http://dx.doi.org/10.1007/s00259-003-1230-1 https://doi.org/10.1007/s00259-003-1230-1
  15. Berg GE., Michanek AM., Holmberg EC., Fink M. Iodine-131 Treatment of Hyperthyroidism: Significance of Effective Half-life Measurements. J Nucl Med 37:228-232, 1996.